FMED Fidelity Disruptive Medicine ETF
ETF 31.74 DelayedETF quote, holdings, sector allocation, technicals, and options analytics. Expected move IV rank history Fibonacci levels
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
- 52-Week Range
- $23.48 – $32.98
- YTD
- +18.04%
- IV Rank (30D)
- 48.19
- Straddle Price
- $2.73
- Open
- $31.97
- Day Range
- $31.97 – $32.11
- Volume
- 1,785
- Prev Close
- $31.99
Fidelity Disruptive Medicine ETF (FMED) ETF
No description available.
- Exchange
- XNAS
- Inception
- 2020-04-16
- Has Options
- Yes
- Expense ratio
- 0.50% issuer, Oct 22, 2026
- Assets
- $52M issuer-reported, Oct 20, 2026
- Trailing yield
- — paid quarterly
- Average daily volume
- $299K 30 sessions
- Holdings
- 77 top 10 are 34.4%
- Listed
- Apr 16, 2020 Nasdaq
- Net asset value
- $32.07 issuer, Oct 21, 2026
- 30-day SEC yield
- -0.36% issuer, Aug 31, 2026
Moves with. US large-cap stocks (13% of its variance, beta 0.48); Small caps over large (12% of its variance, beta 0.62); Long Treasuries (8% of its variance, beta 0.58). These factors explain 38% of its daily moves over the last year.
Stated objective. Fidelity Disruptive Medicine ETF seeks long-term growth of capital. (from the fund's prospectus)
All 77 holdingsFlow historySimilar fundsOverlap toolAll Internet & Innovation ETFs
- May 2026
- −$17M latest reported month
- Latest 3 months
- −$17M −42.4% of assets
- Latest 12 months
- −$12M −29.9% of assets
View as a table
| Month | Net flow |
|---|---|
| May 2026 | −$17M |
| Apr 2026 | $0 |
| Mar 2026 | $0 |
| Feb 2026 | $0 |
| Jan 2026 | $0 |
| Dec 2025 | +$2.8M |
| Nov 2025 | $0 |
| Oct 2025 | $0 |
| Sep 2025 | $0 |
| Aug 2025 | $0 |
| Jul 2025 | $0 |
| Jun 2025 | +$2.4M |
Net creations and redemptions from the fund's SEC filings, which become public about 60 days after each quarter. Every month since 36 months ago
| Fund | Overlap | Fee | Assets | 1Y | |
|---|---|---|---|---|---|
| IBBiShares Biotechnology ETF | 30% | 0.44% | $11.0B | +35.2% | compare |
| MEDIHarbor Health Care ETF | 29% | 0.80% | $41M | +12.2% | compare |
| GDOCGoldman Sachs Future Health Care Equity ETF | 29% | 0.75% | $20M | +11.0% | compare |
| PTHInvesco Exchange-Traded Fund Trust Invesco Dorsey Wright Healthcare Momentum ETF | 27% | 0.60% | $292M | +25.6% | compare |
| GNOMGlobal X Genomics & Biotechnology ETF | 26% | 0.50% | $110M | +54.3% | compare |
Ranked by how much of the two portfolios is the same securities.
- Holdings vs fair value
- −0.9% 24% under, 45% over · 93% covered
- Price / earnings
- — 56% loss-making · 87% covered
- Price / book · sales
- 5.6 · 6.1 revenue growth +7.8%
- Above 200-day average
- 78% 57% above 50-day · by weight
- Short interest
- 9.4% of float, weighted · 5.1 days to cover
- Insider buying
- 5% of weight had net insider buying, 90 days; 64% net selling
- 13F holders
- +3.9% change in shares held by institutions, latest quarter
- Reporting earnings
- 19.5% of weight in 7 days; 62.2% in 14
Each figure is the fund's holdings weighted by position size, using our data on those stocks, and covers only the share of the stock holdings stated. Positive fair value means the holdings trade below our estimate.
| Action | Holding | Weight before | Weight after | Shares vs flows |
|---|---|---|---|---|
| Increase | SEPNSEPTERNA INC | 0.19% | 0.22% | +11.5% |
| Decrease | UPBUPSTREAM BIO INC | 0.03% | 0.02% | −29.9% |
0 new, 0 exited, 1 increased and 1 decreased between the fund's two latest holdings reports; turnover 1.2%. Full holdings and history
- Authorized participants
- 2 active of 25 with agreements; top 3 did 100%
- Created · redeemed
- $5.1M · $17M over the fiscal year
- Redemptions in kind
- 75% creations 79% in kind
- Creation unit
- 100,000 shares
- Securities lending
- 6.42% of assets on loan on average; earned 1.2 bp
From the fund's annual census filing with the SEC. In-kind redemptions are what let an ETF shed appreciated securities without realising gains.
| Ex-Date | Pay Date | Amount | Type |
|---|---|---|---|
| 2024-12-20 | 2024-12-24 | $0.1120 | CD |
| 2024-06-21 | 2024-06-25 | $0.0010 | CD |
| Symbol | Name | Weight % | Asset Class | Country |
|---|---|---|---|---|
| — | SECURITIES LENDING CF | 5.82% | Cash/Money Market | — |
| TXG | 10X GENOMICS INC | 4.49% | Equity (US) | US |
| NTRA | NATERA INC | 4.40% | Equity (US) | US |
| TMO | THERMO FISHER SCIENTIFIC INC | 4.25% | Equity (US) | US |
| DHR | DANAHER CORP | 3.90% | Equity (US) | US |
| ILMN | ILLUMINA INC | 3.52% | Equity (US) | US |
| MRNA | MODERNA INC | 2.86% | Equity (US) | US |
| — | SARTORIUS STEDIM BIOTECH | 2.80% | Equity (Foreign) | FR |
| RVMD | REVOLUTION MEDICINES INC | 2.74% | Equity (US) | US |
| LFST | LIFESTANCE HEALTH GROUP INC | 2.70% | Equity (US) | US |
| ARGX | ARGENX SE SPONSORED ADR | 2.69% | Equity (Foreign) | BE |
| HTFL | HEARTFLOW INC | 2.42% | Equity (US) | US |
| WST | WEST PHARMACEUTICAL SVCS INC | 2.33% | Equity (US) | US |
| ISRG | INTUITIVE SURGICAL INC | 2.29% | Equity (US) | US |
| ALNY | ALNYLAM PHARMACEUTICALS INC | 2.23% | Equity (US) | US |
| KNSA | KINIKSA PHARMACEUTICALS INTERN | 2.06% | Equity (US) | US |
| COGT | COGENT BIOSCIENCES INC | 2.05% | Equity (US) | US |
| GH | GUARDANT HEALTH INC | 2.04% | Equity (US) | US |
| PCVX | VAXCYTE INC | 1.99% | Equity (US) | US |
| KYMR | KYMERA THERAPEUTICS INC | 1.87% | Equity (US) | US |
| VEEV | VEEVA SYS INC CL A | 1.85% | Equity (US) | US |
| ASND | ASCENDIS PHARMA AS | 1.75% | Equity (US) | US |
| RGEN | REPLIGEN | 1.73% | Equity (US) | US |
| ROIV | ROIVANT SCIENCES LTD | 1.58% | Equity (US) | US |
| — | UCB SA | 1.57% | Equity (Foreign) | BE |
| EW | EDWARDS LIFESCIENCES CORP | 1.50% | Equity (US) | US |
| UNH | UNITEDHEALTH GROUP INC | 1.46% | Equity (US) | US |
| INSM | INSMED INC | 1.44% | Equity (US) | US |
| TWST | TWIST BIOSCIENCE CORP | 1.38% | Equity (US) | US |
| VRDN | VIRIDIAN THERAPEUTICS INC | 1.35% | Equity (US) | US |
| AMLX | AMYLYX PHARMACEUTICALS INC | 1.31% | Equity (US) | US |
| WAY | WAYSTAR HOLDING CORP | 1.26% | Equity (US) | US |
| KMTS | KESTRA MEDICAL TECHNOLOGIES IN | 1.20% | Equity (US) | US |
| BTSG | BRIGHTSPRING HLTH SERVICES INC | 1.20% | Equity (US) | US |
| CAI | CARIS LIFE SCIENCES INC | 1.13% | Equity (US) | US |
| AXSM | AXSOME THERAPEUTICS INC | 1.13% | Equity (US) | US |
| BRKR | BRUKER CORP | 1.09% | Equity (US) | US |
| BSX | BOSTON SCIENTIFIC CORP | 1.07% | Equity (US) | US |
| IRON | DISC MEDICINE INC | 1.06% | Equity (US) | US |
| VCYT | VERACYTE INC | 1.04% | Equity (US) | US |
| RLAY | RELAY THERAPEUTICS INC | 0.98% | Equity (US) | US |
| LLY | ELI LILLY & CO | 0.98% | Equity (US) | US |
| DFTX | DEFINIUM THERAPEUTICS INC | 0.97% | Equity (US) | US |
| ELVN | ENLIVEN THERAPEUTICS INC | 0.96% | Equity (US) | US |
| PRAX | PRAXIS PRECISION MEDICINES INC | 0.92% | Equity (US) | US |
| ORKA | ORUKA THERAPEUTICS INC | 0.92% | Equity (US) | US |
| LEGN | LEGEND BIOTECH CORP SPON ADR | 0.88% | Equity (Foreign) | CN |
| MBX | MBX BIOSCIENCES INC | 0.83% | Equity (US) | US |
| STOK | STOKE THERAPEUTICS INC | 0.81% | Equity (US) | US |
| IRTC | IRHYTHM TECHNOLOGIES INC | 0.76% | Equity (US) | US |
| Category | Weight | Value | Positions |
|---|---|---|---|
| Short-term investment | 10.56% | $4.3M | 2 |
| Month | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|
| Jan | -- | -0.23% | 6.25% | -0.80% | 1.74% |
| Feb | -- | 2.69% | -3.46% | -2.44% | -1.07% |
| Mar | -- | 0.71% | -4.76% | -5.57% | -3.21% |
| Apr | -- | -5.55% | 3.34% | 0.47% | -0.58% |
| May | -- | -2.50% | -1.09% | 1.90% | -0.56% |
| Jun | -0.71% | 1.79% | 2.00% | 14.51% | 4.40% |
| Jul | 1.91% | 3.45% | -1.13% | -3.43% | 0.20% |
| Aug | -5.07% | 3.95% | 3.98% | 12.71% | 3.89% |
| Sep | -7.96% | 1.96% | 1.59% | 2.63% | -0.45% |
| Oct | -7.40% | -2.37% | 4.27% | 1.30%* | -1.05% |
| Nov | 5.78% | 1.95% | 10.85% | -- | 6.19% |
| Dec | 10.89% | -6.07% | -4.65% | -- | 0.06% |
| Total | -3.97% | -0.85% | 17.23% | 21.24% | 8.41% |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
LLM Stock Analysis Report
Executive Summary BULLISH (Confidence Level: 6/10)
Key drivers:
- Bullish MACD signal
- Neutral RSI reading
- Supportive volume patterns
Primary risks:
- Resistance at upper Bollinger Band
- Volatility levels above historical average
Investment thesis: FMED is poised to break out of its current trading range, driven by positive momentum signals and supportive volume indicators. However, the stock's high volatility and potential resistance at the upper Bollinger Band pose significant risks.
Recent news sentiment impact: No recent news headlines available, which may be contributing to the stock's neutral sentiment.
Technical Analysis
Trend Direction:
- Short-term: Uptrend (1-4 weeks)
- Medium-term: Uptrend (1-3 months)
- Long-term: Neutral (3-12 months)
Support/Resistance Levels:
- Lower Bollinger Band ($27.41) - key support level
- Upper Bollinger Band ($30.84) - potential resistance level
Momentum Signals:
- MACD signal: Bullish
- RSI reading: 68.52 (neutral)
- Bollinger Bands: Neutral
Volume Analysis:
- Volume SMA 20: 3754.58
- On-Balance Volume (OBV): 612950.88
- Volume Rate of Change: 94.11% - indicates increasing volume and institutional interest.
News & Sentiment Analysis
Recent Headlines Summary: No recent news headlines available
Sentiment Assessment: Neutral sentiment due to lack of recent news
Catalyst Identification: None currently identified, but potential earnings release or product launch could drive price movements.
Market Narrative: FMED's neutral market narrative is driven by its moderate volatility and lack of significant news events recently.
Risk & Volatility Assessment
Beta Interpretation:
- Beta: 0.82 (moderate risk relative to SPY)
Volatility Regime:
- Current vs historical volatility levels: Higher than average, but not excessively high
Options Market Signals:
- IV Rank: 19.5% (Low) - suggests low volatility and potential for a relatively calm market
- Put/Call Volume Ratio: 0.00 (Neutral sentiment) - no significant bias in options trading activity
- Unusual activity: None identified
Downside Protection:
- Support levels: Lower Bollinger Band ($27.41)
- Risk management considerations: Stop-loss levels and position sizing considerations based on volatility and market conditions.
Market Context & Positioning
Sector Performance:
- Relative strength vs sector/market: FMED is neutral to slightly above-average in its sector
Institutional Activity:
- Volume patterns suggesting institutional interest: Increasing volume and OBV signals growing institutional interest.
Correlation Analysis:
- How stock moves relative to market (R-squared interpretation): 0.52 - indicates moderate correlation with the overall market
Relative Valuation:
- Position within trading range: FMED is near the upper end of its trading range, potentially poised for a breakout or consolidation.
Key Levels & Action Items
Critical Price Levels:
- Support: Lower Bollinger Band ($27.41)
- Resistance: Upper Bollinger Band ($30.84)
Breakout/Breakdown Levels:
- Breakout level: $31.10 (upper end of the trading range)
- Breakdown level: $28.17 (lower end of the trading range)
Time-Sensitive Catalysts:
- Earnings release date: None currently identified
- Product launch date: None currently identified
Risk Management:
- Stop-loss levels: Based on volatility and market conditions, consider setting stop-loss at $29.00 or $27.50
- Position sizing considerations: Adjust position size based on risk tolerance and market conditions.
By analyzing the provided data, we can conclude that FMED is likely to experience a short-term uptrend driven by positive momentum signals and supportive volume indicators. However, the stock's high volatility and potential resistance at the upper Bollinger Band pose significant risks. A conservative approach with a focus on risk management would be advisable, considering stop-loss levels and position sizing considerations based on volatility and market conditions.
FMED Options Activity & IV Rank
FMED IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Options Flow
ATM Options Pricing
Chain Summary
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Enter a ticker to render the implied volatility surface.
Enter a ticker to render the implied volatility smile.
Risk Metrics
Analysis Details
Data Points: 251
Period: 252 trading days
Moderate volatility - stock generally follows market
FMED Institutional Ownership (13F)
Latest filings — 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Click any bar to view the full quote for that stock.
| Symbol | Name | Weight % | Price | 1 Day | 1 Week | 1 Month |
|---|---|---|---|---|---|---|
| TXG | 10X GENOMICS INC | 4.49% | $70.39 | -6.89% | -2.77% | -16.32% |
| NTRA | NATERA INC | 4.40% | $399.43 | -3.37% | -1.32% | -2.29% |
| TMO | THERMO FISHER SCIENTIFIC INC | 4.25% | $686.35 | -1.11% | -1.46% | +1.17% |
| DHR | DANAHER CORP | 3.90% | $233.13 | -0.31% | +0.70% | +4.18% |
| ILMN | ILLUMINA INC | 3.52% | $270.27 | -4.45% | +0.87% | -1.33% |
| MRNA | MODERNA INC | 2.86% | $230.99 | -6.03% | -2.33% | +18.57% |
| RVMD | REVOLUTION MEDICINES INC | 2.74% | $186.61 | -3.95% | -1.40% | -6.63% |
| LFST | LIFESTANCE HEALTH GROUP INC | 2.70% | $12.37 | +0.32% | +0.00% | +4.83% |
| ARGX | ARGENX SE SPONSORED ADR | 2.69% | $886.64 | -0.38% | +4.77% | -7.85% |
| HTFL | HEARTFLOW INC | 2.42% | $55.36 | -0.82% | +8.75% | +13.77% |
| WST | WEST PHARMACEUTICAL SVCS INC | 2.33% | $392.91 | -0.14% | +2.58% | +5.17% |
| ISRG | INTUITIVE SURGICAL INC | 2.29% | $440.29 | +2.84% | +2.90% | +10.20% |
| ALNY | ALNYLAM PHARMACEUTICALS INC | 2.23% | $226.7 | +0.71% | -3.13% | -9.17% |
| KNSA | KINIKSA PHARMACEUTICALS INTERN | 2.06% | $80.42 | +0.90% | +0.60% | +6.74% |
| COGT | COGENT BIOSCIENCES INC | 2.05% | $31.12 | -0.97% | +5.47% | -0.97% |
| GH | GUARDANT HEALTH INC | 2.04% | $163.16 | -2.10% | -1.64% | -7.53% |
| PCVX | VAXCYTE INC | 1.99% | $61.78 | -2.29% | -5.34% | +8.59% |
| KYMR | KYMERA THERAPEUTICS INC | 1.87% | $112.62 | -0.01% | +4.14% | -2.75% |
| VEEV | VEEVA SYS INC CL A | 1.85% | $321.92 | +0.43% | +2.84% | +17.13% |
| ASND | ASCENDIS PHARMA AS | 1.75% | $241.46 | +1.07% | +6.55% | +4.66% |
| RGEN | REPLIGEN | 1.73% | $182.61 | +1.44% | -0.85% | -4.22% |
| ROIV | ROIVANT SCIENCES LTD | 1.58% | $37.74 | +2.55% | +10.87% | +4.46% |
| EW | EDWARDS LIFESCIENCES CORP | 1.50% | $89.36 | +1.09% | +1.43% | +4.23% |
| UNH | UNITEDHEALTH GROUP INC | 1.46% | $424.98 | +1.91% | +4.50% | +13.32% |
| INSM | INSMED INC | 1.44% | $93.86 | -0.19% | -5.39% | -22.78% |
| TWST | TWIST BIOSCIENCE CORP | 1.38% | $141.12 | -5.37% | -2.34% | -23.32% |
| VRDN | VIRIDIAN THERAPEUTICS INC | 1.35% | $23.14 | +0.54% | +18.28% | +11.98% |
| AMLX | AMYLYX PHARMACEUTICALS INC | 1.31% | $29.79 | +2.62% | +7.74% | -1.16% |
| WAY | WAYSTAR HOLDING CORP | 1.26% | $28.71 | -0.45% | +1.66% | +16.52% |
| KMTS | KESTRA MEDICAL TECHNOLOGIES IN | 1.20% | $28.73 | +5.18% | +0.16% | +11.51% |
| BTSG | BRIGHTSPRING HLTH SERVICES INC | 1.20% | $60.81 | -2.49% | -2.49% | +8.55% |
| CAI | CARIS LIFE SCIENCES INC | 1.13% | $31.55 | -2.46% | -0.65% | -2.22% |
| AXSM | AXSOME THERAPEUTICS INC | 1.13% | $154.77 | -0.99% | -4.34% | -21.05% |
| BRKR | BRUKER CORP | 1.09% | $56.95 | -3.65% | +0.73% | -11.02% |
| BSX | BOSTON SCIENTIFIC CORP | 1.07% | $45.3 | +1.79% | +2.64% | +1.40% |
| IRON | DISC MEDICINE INC | 1.06% | $75.75 | -0.34% | +33.71% | +14.01% |
| VCYT | VERACYTE INC | 1.04% | $46.1 | -0.25% | +3.86% | -5.02% |
| RLAY | RELAY THERAPEUTICS INC | 0.98% | $18.27 | -0.76% | +5.61% | +3.05% |
| LLY | ELI LILLY & CO | 0.98% | $1314.83 | +3.47% | +5.05% | +11.25% |
| DFTX | DEFINIUM THERAPEUTICS INC | 0.97% | $35.91 | +1.17% | +4.80% | -2.25% |
| ELVN | ENLIVEN THERAPEUTICS INC | 0.96% | $41.86 | +0.10% | +6.43% | -7.33% |
| PRAX | PRAXIS PRECISION MEDICINES INC | 0.92% | $257.9 | +0.56% | +3.89% | -8.48% |
| ORKA | ORUKA THERAPEUTICS INC | 0.92% | $80.64 | +0.90% | +9.16% | -5.67% |
| LEGN | LEGEND BIOTECH CORP SPON ADR | 0.88% | $18.77 | +0.72% | -5.23% | -1.55% |
| MBX | MBX BIOSCIENCES INC | 0.83% | $52.82 | -2.06% | +4.16% | -4.64% |
| STOK | STOKE THERAPEUTICS INC | 0.81% | $26.15 | +1.83% | +6.26% | +3.40% |
| IRTC | IRHYTHM TECHNOLOGIES INC | 0.76% | $114.92 | +1.21% | +5.09% | +3.72% |
| ZLAB | ZAI LAB LTD UNSPNRD ADR | 0.74% | $22.32 | -7.77% | -5.06% | -11.71% |
| NAMS | NEWAMSTERDAM PHARMA COMPANY NV | 0.70% | $21.73 | +1.14% | +5.41% | -4.42% |
| DXCM | DEXCOM INC | 0.66% | $78.78 | -1.84% | -10.18% | -9.93% |